At Forbion Capital Partners we invest in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development.
The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. We focus on companies that have innovative technologies and drug development programs with unique advantages over current treatments. Furthermore, we invest in medical device companies with a focus on interventional cardiology and gastroenterology.
Our involvement continues beyond the initial investment. We work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of our portfolio company's technologies.
The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Throughout this time the Forbion team made new investments and has successfully divested from a series of companies. Forbion currently has EUR 200 million under management.